Physician profile
James C Meyer
NPI 1063484228
$2,288.10
in general payments reported to CMS, 2019-2025
22 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $382 · 2021: $397 · 2022: $350 · 2023: $535 · 2024: $150 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Consulting Fee: $400 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.62 |
| Consulting Fee | $400.00 |
| Education | $117.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $525.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.70 | 2019-2023 | |
| Harmony Biosciences LLC | $282.97 | 2021-2024 | Wakix |
| Glaxosmithkline, LLC. | $260.29 | 2019-2023 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $166.60 | 2019-2023 | Breztri |
| Genzyme Corporation | $156.94 | 2020-2023 | |
| Mylan Specialty L.P. | $108.72 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $86.48 | 2019-2023 | |
| Philips North America LLC | $78.51 | 2020-2025 | (Di7) Home Pi Undivided, Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $49.32 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $40.39 | 2019-2025 | Dupixent |
| Insmed, INC. | $33.62 | 2020-2025 | Brinsupri |
| Pulmonx Corporation | $29.18 | 2022 | |
| Inspire Medical Systems, INC. | $27.90 | 2025 | Inspire |
| United Therapeutics Corporation | $22.70 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $19.21 | 2022 | |
| 180 Medical, INC. | $15.92 | 2022 | |
| Eisai INC. | $14.36 | 2020 | |
| Pfizer INC. | $13.28 | 2021 | |
| Advanced Respiratory, INC | $13.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.98 | 2020 | |
| Electromed, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.